CeriBell (NASDAQ:CBLL) CRO Joseph Manni Sells 1,361 Shares

CeriBell, Inc. (NASDAQ:CBLL) CRO Joseph Manni sold 1,361 shares of CeriBell stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $24.02, for a total transaction of $32,691.22. Following the sale, the executive directly owned 55,956 shares in the company, valued at $1,344,063.12. This trade represents a 2.37% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

CeriBell Price Performance

CBLL stock opened at $23.95 on Wednesday. The stock has a market cap of $919.20 million, a price-to-earnings ratio of -13.61 and a beta of 0.81. The company has a debt-to-equity ratio of 0.16, a current ratio of 9.18 and a quick ratio of 8.79. The company has a 50 day simple moving average of $19.77 and a 200 day simple moving average of $19.27. CeriBell, Inc. has a 1 year low of $10.85 and a 1 year high of $25.33.

CeriBell (NASDAQ:CBLL) last posted its earnings results on Monday, August 10th. The company reported ($0.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.04). The company had revenue of $28.10 million for the quarter, compared to the consensus estimate of $27.28 million. CeriBell had a negative return on equity of 44.85% and a negative net margin of 64.73%. Research analysts anticipate that CeriBell, Inc. will post -1.96 EPS for the current fiscal year.

Institutional Trading of CeriBell

Several institutional investors have recently modified their holdings of CBLL. Caitong International Asset Management Co. Ltd increased its holdings in CeriBell by 3,971.0% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock valued at $28,000 after purchasing an additional 1,231 shares during the period. Strs Ohio acquired a new position in CeriBell during the 1st quarter worth about $27,000. CWM LLC grew its position in shares of CeriBell by 1,178.5% in the 4th quarter. CWM LLC now owns 1,841 shares of the company’s stock valued at $40,000 after buying an additional 1,697 shares during the last quarter. Tower Research Capital LLC TRC grew its position in shares of CeriBell by 353.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock valued at $43,000 after buying an additional 1,801 shares during the last quarter. Finally, Legal & General Group Plc acquired a new stake in shares of CeriBell in the second quarter valued at about $53,000.

CeriBell News Summary

Here are the key news stories impacting CeriBell this week:

• Neutral Sentiment: CEO Xingjuan Chao, CFO Scott Blumberg, CTO Raymond Woo, CRO Joseph S. Manni and VP David Foehr collectively sold approximately 12,781 shares for about $307,000. Each filing stated that the shares were sold to cover tax-withholding obligations after equity awards vested, and the executives retained substantial remaining holdings. SEC insider transaction filings
• Neutral Sentiment: Reported short interest was zero shares as of August 25, unchanged from zero shares on August 10, with a zero-day days-to-cover ratio. Because the figures include a “NaN” change and may reflect incomplete or anomalous reporting, they provide little actionable information about bearish positioning.
• Negative Sentiment: The cluster of sales by multiple senior executives could create a modest overhang for CBLL, particularly with the stock trading close to its 12-month peak. However, the relatively small size of the transactions and their stated tax-related purpose lessen the signal that management is broadly reducing exposure.

Analyst Ratings Changes

A number of brokerages recently weighed in on CBLL. Barclays upgraded CeriBell to a “neutral” rating in a research report on Tuesday, August 18th. Canaccord Genuity Group lifted their price target on CeriBell from $25.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, August 11th. Weiss Ratings upgraded CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 13th. Finally, BTIG Research upped their price objective on CeriBell from $28.00 to $30.00 and gave the company a “buy” rating in a research note on Tuesday, August 18th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $22.40.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.